Abstract:A complementary immunotherapeutic platform is constructed using DC‐tumor chimeric exosomes cooperated with exogenous CDN‐driven STING activation for maximized tumor‐specific T‐cell immunity. These chimeric nanovesicles provide advantages versus existing CDN delivery technologies in 1) the supply of broad‐spectrum tumor antigen complexes for dual T‐cell activation; 2) the cytosolic delivery of STING agonists for enhanced antigen presentation; and 3) the brilliant BBB‐crossing capacity. A critical challenge of existing cancer vaccines is to orchestrate the demands of antigen‐enriched furnishment and optimal antigen‐presentation functionality within antigen‐presenting cells (APCs). Here, a complementary immunotherapeutic strategy is developed using dendritic cell (DC)‐tumor hybrid cell‐derived chimeric exosomes loaded with stimulator of interferon genes (STING) agonists (DT‐Exo‐STING) for maximized tumor‐specific T‐cell immunity. These chimeric carriers are furnished with broad‐spectrum antigen complexes to elicit a robust T‐cell‐mediated inflammatory program through direct self‐presentation and indirect DC‐to‐T immunostimulatory pathway. This chimeric exosome‐assisted delivery strategy possesses the merits versus off‐the‐shelf cyclic dinucleotide (CDN) delivery techniques in both the brilliant tissue‐homing capacity, even across the intractable blood–brain barrier (BBB), and the desired cytosolic entry for enhanced STING‐activating signaling. The improved antigen‐presentation performance with this nanovaccine‐driven STING activation further enhances tumor‐specific T‐cell immunoresponse. Thus, DT‐Exo‐STING reverses immunosuppressive glioblastoma microenvironments to pro‐inflammatory, tumoricidal states, leading to an almost obliteration of intracranial primary lesions. Significantly, an upscaling option that harnesses autologous tumor tissues for personalized DT‐Exo‐STING vaccines increases sensitivity to immune checkpoint blockade (ICB) therapy and exerts systemic immune memory against post‐operative glioma recrudesce. These findings represent an emerging method for glioblastoma immunotherapy, warranting further exploratory development in the clinical realm.

Exosome-loaded dendritic cells elicit tumor-specific CD8 + cytotoxic T cells in patients with glioma

The Experiment on the Anti- glioma Effects of Exosome Loaded Dendritic Cells Vaccine

Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice

Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas

The Dual Role of Glioma Exosomal Micrornas: Glioma Eliminates Tumor Suppressor Mir-1298-5p Via Exosomes to Promote Immunosuppressive Effects of MDSCs

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

Co-delivery of Tumor-Derived Exosomes with Alpha-Galactosylceramide on Dendritic Cell-Based Immunotherapy for Glioblastoma

Exosome from Chaperone-Rich Cell Lysates-Loaded Dendritic Cells Produced by CELLine 1000 Culture System Exhibits Potent Immune Activity

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

The Anti-Tumor Activity of Dendritic Cell/cytotoxic T Lymphocyte Induced by Cholangiocarcinoma-Derived Exosome and Its Ultrafiltered Lysate

Exosomal LGALS9 in the Cerebrospinal Fluid of Glioblastoma Patients Suppressed Dendritic Cell Antigen Presentation and Cytotoxic T-cell Immunity

Experimental Study of Treatment ofIntracranial G422 Glioblastoma with Bone Marrow-derived Dendritic Cells Vaccine

Glioma Stem Cell-Targeted Dendritic Cells As A Tumor Vaccine Against Malignant Glioma

Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy

Downregulation of Exosomal MHC-I Promotes Glioma Cells Escaping from Systemic Immunosurveillance.

Glioblastoma cell-derived exosomes functionalized with peptides as efficient nanocarriers for synergistic chemotherapy of glioblastoma with improved biosafety

Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes

In Situ Sprayed Exosome-Cross-Linked Gel as Artificial Lymph Nodes for Postoperative Glioblastoma Immunotherapy

Mesenchymal stem cells, as glioma exosomal immunosuppressive signal multipliers, enhance MDSCs immunosuppressive activity through the miR-21/SP1/DNMT1 positive feedback loop

Experimental study on the mechanism of immunotherapy in human brain malignant gliomas with dendritic cell vaccine targeting of cancer stem cell in vitro